The first GLP-1 receptor agonist approved in the US — derived from Gila monster saliva with decades of clinical data.
Exenatide is a synthetic version of exendin-4 — a 39-amino acid peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). It was the first GLP-1 receptor agonist approved by the FDA (as Byetta in 2005), predating liraglutide and semaglutide. A long-acting depot formulation (Bydureon/Bydureon BCise) was approved in 2012 for once-weekly dosing.
Exendin-4 shares approximately 53% homology with human GLP-1 but is resistant to the DPP-4 enzyme that rapidly degrades native GLP-1. This resistance gives exenatide a clinically useful half-life. The Gila monster produces exendin-4 to regulate its metabolism during infrequent feeding — it can go months between meals.
While newer GLP-1 agents (semaglutide, tirzepatide) have largely supplanted exenatide for new prescriptions, it retains clinical relevance as the first-in-class agent with the longest track record of safe use.
Multiple Phase 3 trials demonstrated exenatide reduces HbA1c by 0.8-1.5% and promotes weight loss of 2-5 kg. The EXSCEL cardiovascular outcomes trial showed cardiovascular safety but did not demonstrate superiority over placebo for cardiovascular event reduction.
Exenatide has been studied for neuroprotection in Parkinson's disease, with Phase 2 data suggesting potential disease-modifying effects — an unexpected finding that has generated significant interest in GLP-1 agonists for neurological conditions.
📚 Key Reference: PMID: 15929049 (exenatide Phase 3), PMID: 28888525 (Parkinson's Phase 2)
GI side effects (nausea, vomiting, diarrhea) are common, especially with Byetta. Bydureon has fewer GI effects but injection site nodules. Pancreatitis risk (rare). Thyroid C-cell tumor warnings. Renal function should be monitored. Consult your provider.
FDA-approved as Byetta (twice daily, 2005) and Bydureon BCise (weekly, 2012). AstraZeneca.